We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly plans to launch two new cheaper insulin products amid criticism about the availability of its lower-cost insulins on pharmacy shelves. Read More
The U.S. Supreme Court this week opted not to take up a patent suit between Vanda Pharmaceuticals and generic drugmaker Hikma Pharmaceuticals over Vanda’s schizophrenia treatment Fanapt (iloperidone). Read More
Republicans on the House Energy and Commerce Committee on Tuesday revived their investigation into the role three drugmakers played in the opioid crisis, pressing Insys, Mallinckrodt and Purdue Pharma for more details. Read More
Three acute treatments for migraine — Eli Lilly’s Reyvow (lasmiditan), Biohaven’s rimegepant, and Allergan’s Ubrelvy (ubrogepant) — may not be cost-effective, according to the Institute for Clinical and Economic Review (ICER). Read More
Biogen has agreed to purchase Pfizer’s early-stage neurological disease drug for $75 million plus royalties and up to $635 million in future payments. The acquisition of PF-05251749 marks the latest move by Biogen into potential treatments for neurological diseases. Read More
The European Commission has approved AbbVie’s $63 billion acquisition of Allergan on condition that the companies sell off Allergan’s investigational treatment for inflammatory bowel disease (IBD). Read More